Comparison of Pharmacodynamics between Tegoprazan and Dexlansoprazole Regarding Nocturnal Acid Breakthrough: A Randomized Crossover Study
Gut and Liver · 15.01.2023 · 17 (1) · 92-99
DOI: 10.5009/gnl220050 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Gut and Liver, online erschienen am 01.11.2022. Verfasst von Sungpil Han und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, College of Medicine, The Catholic University of Korea, Seoul, Korea. Hauptthemen laut MEDLINE: Proton Pump Inhibitors, Benzene Derivatives. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: HK inno.N Corp.
Abstract (Originalsprache)
Background/Aims: Tegoprazan, a novel potassium-competitive acid blocker, is expected to overcome the limitations of proton pump inhibitors and effectively control nocturnal acid breakthrough. To evaluate the pharmacodynamics of tegoprazan versus dexlansoprazole regarding nocturnal acid breakthrough in healthy subjects.
Methods
In a randomized, open-label, single-dose, balanced incomplete block crossover study, 24 healthy male volunteers were enrolled and randomized to receive oral tegoprazan (50, 100, or 200 mg) or dexlansoprazole (60 mg) during each of two administration periods, separated by a 7- to 10-day washout period. Blood samples were collected for pharmacokinetic parameter analysis; gastric monitoring was performed for pharmacodynamic parameter evaluation.
Results
All 24 subjects completed the study. Average maximum plasma concentration, area under the plasma concentration-time curve, and mean time with gastric pH >4 and pH >6 for tegoprazan demonstrated dose-dependent incremental increases. All the tegoprazan groups reached mean pH ≥4 within 2 hours, whereas the dexlansoprazole group required 7 hours after drug administration. Based on pharmacodynamic parameters up to 12 hours after evening dosing, 50, 100, and 200 mg of tegoprazan presented a stronger acid-suppressive effect than 60 mg of dexlansoprazole. Moreover, the dexlansoprazole group presented a comparable acid-suppressive effect with the tegoprazan groups 12 hours after dosing.
Conclusions
All the tegoprazan groups demonstrated a significantly faster onset of gastric pH increase and longer holding times above pH >4 and pH >6 up to 12 hours after evening dosing than the dexlansoprazole group.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, College of Medicine, The Catholic University of Korea, Seoul, Korea.
- Department of Clinical Pharmacology and Therapeutics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
- Clinical Development, HK inno.N Corp., Seoul, Korea.
ORCID-Profile: Sungpil Han, Hee Youn Choi, Yo Han Kim, SeungChan Choi, Seokuee Kim, Ji Yeon Nam, Bongtae Kim, Geun Seog Song, Hyeong-Seok Lim, Kyun-Seop Bae
Förderung
- HK inno.N Corp
Zitieren
APA
Han, S., Choi, H. Y., Kim, Y. H., Choi, S., Kim, S., Nam, J. Y., Kim, B., Song, G. S., Lim, H. S., & Bae, K. S. (2023). Comparison of Pharmacodynamics between Tegoprazan and Dexlansoprazole Regarding Nocturnal Acid Breakthrough: A Randomized Crossover Study. Gut and Liver, 17(1), 92-99. https://doi.org/10.5009/gnl220050
Vancouver
Han S, Choi HY, Kim YH, Choi S, Kim S, Nam JY, et al. Comparison of Pharmacodynamics between Tegoprazan and Dexlansoprazole Regarding Nocturnal Acid Breakthrough: A Randomized Crossover Study. Gut and Liver. 2023;17(1):92-99. doi:10.5009/gnl220050
BibTeX
@article{Han2023,
author = {Han, Sungpil and Choi, Hee Youn and Kim, Yo Han and Choi, SeungChan and Kim, Seokuee and Nam, Ji Yeon and Kim, Bongtae and Song, Geun Seog and Lim, Hyeong-Seok and Bae, Kyun-Seop},
title = {Comparison of Pharmacodynamics between Tegoprazan and Dexlansoprazole Regarding Nocturnal Acid Breakthrough: A Randomized Crossover Study},
journal = {Gut and Liver},
year = {2023},
volume = {17},
number = {1},
pages = {92--99},
doi = {10.5009/gnl220050}
}
EUVIMED